SEARCH:   Advanced

Blood, 1 May 2005, Vol. 105, No. 9, pp. 3428-3433. Prepublished online as a Blood First Edition Paper on January 6, 2005; DOI 10.1182/blood-2004-06-2490. This Article Full Text (PDF) All Versions of this Article: 2004-06-2490v1 105/9/3428    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rambaldi, A. Articles by Foa, R. Search for Related Content PubMed PubMed Citation Articles by Rambaldi, A. Articles by Foa, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 30, 2004 Accepted December 24, 2004 Quantitative PCR of bone marrow BCL2/IgH positive cells at diagnosis predicts treatment response and long-term outcome in Follicular non Hodgkin's Lymphoma Alessandro Rambaldi*, Emanuela Carlotti, Elena Oldani, Irene Della Starza, Michele Baccarani, Sergio Cortelazzo, Francesco Lauria, Luca Arcaini, Enrica Morra, Alessandro Pulsoni, Luigi Rigacci, Maurizio Rupolo, Francesco Zaja, Pier L Zinzani, Tiziano Barbui, and Robert Foa Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita 'La Sapienza', Roma, Italy Istituto di Ematologia e Oncologia Medica Seragnoli, Universita di Bologna, Bologna, Italy Cattedra di Ematologia, Universita di Siena, Siena, Italy Divisione di Ematologia IRCCS, Policlinico San Matteo, Universita di Pavia, Pavia, Italy Divisione di Ematologia, Ospedale Niguarda, Milano, Italy Cattedra di Ematologia, Universita di Firenze, Firenze, Italy Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy Cattedra di Ematologia, Universita di Udine, Udine, Italy * Corresponding author; email: arambaldi{at}ospedaliriuniti.bergamo.it. By real time quantitative PCR reaction (RQ-PCR) we evaluated BCL2/IgH+ cells in the bone marrow (BM) and peripheral blood (PB) of 86 follicular lymphoma patients treated with the sequential administration of CHOP and Rituximab. At diagnosis, the amount of BCL2/IgH+ cells in the BM was low (1 BCL2/IgH+ cell in 1000 / 100,000 normal cells) in 43% of patients, intermediate (1 in 100 / 1000) in 34% or high ( >1 in 100) in 23%. A 2 log decrease of BCL2/IgH+ cells was achieved after CHOP and an additional 2 log reduction following Rituximab. By multivariate analysis, a low level of BCL2/IgH+ cells in the BM at diagnosis was the best predictor for the achievement of a complete clinical and molecular response. At 5 years, the event-free survival of patients with a low/intermediate or high tumor infiltration in the BM was 59% and 32%, respectively. The freedom from recurrence of patients who achieved a molecular response in the BM, no matter whether after CHOP alone or CHOP and Rituximab, was 64% as compared to 32% for patients who did not (p< 0.006). RQ-PCR performed at presentation on BM samples predicts treatment response and long-term clinical outcome in follicular lymphoma patients CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R B Ilgenfritz, K Kayasut, A Le Tourneau, O A Calendini, L Ouafi, C Marzac, J Diebold, F Devez, V Ducruit, P E Bouchet, et al. Correlation between molecular and histopathological diagnoses of B cell lymphomas in bone marrow biopsy and aspirates J. Clin. Pathol., April 1, 2009; 62(4): 357 - 360. [Abstract] [Full Text] [PDF] M. Foglietta, S. S. Neelapu, and L. W. Kwak Therapeutic Vaccines for Lymphoma: From Bench to Bedside ASCO Educational Book, January 1, 2009; 2009(1): 495 - 500. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] S. Montoto, C. Moreno, E. Domingo-Domenech, C. Estany, A. Oriol, A. Altes, J. Besalduch, C. Pedro, S. Gardella, L. Escoda, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma Haematologica, February 1, 2008; 93(2): 207 - 214. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF] S. S. Neelapu and L. W. Kwak Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies Hematology, January 1, 2007; 2007(1): 243 - 249. [Abstract] [Full Text] [PDF] C. Pott, C. Schrader, S. Gesk, L. Harder, M. Tiemann, T. Raff, M. Bruggemann, M. Ritgen, B. Gahn, M. Unterhalt, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma Blood, March 15, 2006; 107(6): 2271 - 2278. [Abstract] [Full Text] [PDF] N. Pennell, A. Woods, M. Reis, R. Buckstein, D. Spaner, K. Imrie, K. Hewitt, A. Boudreau, A. Seth, and N. L. Berinstein Association of Clinical Status of Follicular Lymphoma Patients after Autologous Stem Cell Transplant and Quantitative Assessment of Lymphoma in Blood and Bone Marrow as Measured by SYBR Green I Polymerase Chain Reaction J. Mol. Diagn., February 1, 2006; 8(1): 40 - 50. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020